Spectrum Of Activity
Complicated SSTI, intraabdominal infectionCAP100 mg IV 1 dose, then 50 mg IV q12h x5-14d100 mg IV dose, then 50 mg IV q12h x7-14dNo renal dose adjustment
Usual doseUse in pediatric patients <8y of age is not recommended because of the effect on tooth development
Safety and efficacy in pediatric patients <18y of age have not been established- Age 8-11y without alternative option: 1.2 mg/kg IV q12h (max 50 mg/dose)
- Age 12-18y without alternative option: 50 mg IV q12hNo renal dose adjustment
Mild or moderate hepatic impairmentSevere hepatic impairmentNo dosage adjustment100 mg IV loading, then 25 mg IV q12h
Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility.
Black Box Warning: Associated with more treatment failures than alternatives and excess mortality. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.
Perform bacteriological examination and sensitivity testing during initiation and for suspected relapse.
Monitor hepatic function for patients with abnormal liver function test, and severe hepatic impairment.
Obtain baseline blood coagulation panel, including fibrinogen, and monitor regularly during treatment.
Clostridioides difficile infection
Increased liver enzymes
- Acitretin - may result in increased risk of pseudotumor cerebri
Cholera vaccine, live
Antimicrobial class: Tetracycline derivative, Glycylcycline
Pregnancy category: D
Average serum half life: 42 hours
Biliary penetration: Therapeutic
Lung penetration: Therapeutic
Requires Infectious Disease consultation.
Documented safety concerns in bacteremia especially.